PMID- 33511186
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210130
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 9
IP  - 1
DP  - 2021 Jan 6
TI  - Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth 
      factor receptor beta gene in children: Two case reports.
PG  - 204-210
LID - 10.12998/wjcc.v9.i1.204 [doi]
AB  - BACKGROUND: Myeloid neoplasm (MN) with eosinophilia and rearrangement of 
      platelet-derived growth factor receptor beta (PDGFRB) shows a good therapeutic 
      response to imatinib in adults. MN is rarely found in children, and the efficacy 
      of imatinib on pediatric patients remain unclear. CASE SUMMARY: We report 2 
      pediatric cases diagnosed with MN with eosinophilia and PDGFRB rearrangement who 
      were treated with imatinib. Case 1 was a 1-year-old girl admitted to the hospital 
      because of "abdominal distension with hyperleukocytosis for 3 mo". She had 
      leukocytosis, anemia, and eosinophilia (the absolute eosinophil count (AEC) was 
      8960/muL), and her fluorescence in situ hybridization (FISH) test revealed that 
      PDGFRB rearrangement was detected in 70% of 500 interphase cells. Case 2 was a 
      2-year-old girl admitted to the hospital because of "recurrent fever and rashes 
      for 1 mo". Her blood cell count showed an AEC of 3540/muL. The FISH test revealed 
      that PDGFRB rearrangement was detected in 71% of 500 interphase cells. Both 
      patients were diagnosed as MN with eosinophilia and PDGFRB rearrangement. 
      Imatinib was added into their treatment regimen. As expected, complete 
      hematologic remission was achieved after 1 mo of treatment, and symptoms 
      disappeared. CONCLUSION: Although MN with eosinophilia and PDGFRB rearrangement 
      usually occurs in adults, it can be found in children. The therapeutic benefits 
      of imatinib in these 2 pediatric patients were consistent with its reported 
      effects in adult patients.
CI  - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Wang, Shi-Chong
AU  - Wang SC
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Yang, Wen-Yu
AU  - Yang WY
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China. yangwenyu@ihcams.ac.cn.
LA  - eng
PT  - Case Reports
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC7809671
OTO - NOTNLM
OT  - Case report
OT  - Children
OT  - Eosinophilia
OT  - Imatinib
OT  - Myeloid neoplasm
OT  - Platelet-derived growth factor receptor beta rearrangement
COIS- Conflict-of-interest statement: The authors declare no conflicts of interest.
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
PMCR- 2021/01/06
CRDT- 2021/01/29 05:57
PHST- 2020/06/24 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2021/01/29 05:57 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
PHST- 2021/01/06 00:00 [pmc-release]
AID - 10.12998/wjcc.v9.i1.204 [doi]
PST - ppublish
SO  - World J Clin Cases. 2021 Jan 6;9(1):204-210. doi: 10.12998/wjcc.v9.i1.204.